欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学

• 学术动态 • 上一篇    下一篇

PROfound研究——前列腺癌精准治疗新希望

黄后宝   

  1. 皖南医学院第一附属医院泌尿外科,芜湖 241001,安徽
  • 收稿日期:2020-02-21 修回日期:2020-02-23 出版日期:2020-02-26 发布日期:2020-03-06
  • 作者简介:黄后宝,男,医学硕士,教授,硕士生导师,皖南医学院第一附属医院副院长、泌尿外科主任医师,安徽省健康服务业协会泌尿男科健康分会会长,安徽省病案质控中心主任。现为《中国临床药理学与治疗学》《皖南医学院学报》等多家学术期刊编委。

PROfound: A new hope for precise treatment of prostate cancer

HUANG Houbao   

  1. Department of Urology, the First Affiliated Hospital of Wannan Medical College, Wuhu 241001, Anhui, China
  • Received:2020-02-21 Revised:2020-02-23 Online:2020-02-26 Published:2020-03-06

摘要: 转移性去势抵抗性前列腺癌(metastatic castrate-resistant prostate cancer,mCRPC)是前列腺癌发展的终末阶段。患者生存预后很差。尽管不断地有新的治疗手段出现,比如新型内分泌治疗以及紫杉醇类化疗,mCRPC患者的生存期依然很有限。奥拉帕利是一款聚腺苷酸二磷酸核糖基聚合酶(poly ADP-ribose polymerase,PARP)抑制剂,PARP酶在DNA修复中扮演着重要的角色。奥拉帕利已经获批用于卵巢癌和乳腺癌的治疗。目前,奥拉帕利用于mCRPC治疗的III期临床研究PROfound的结果在2019年的欧洲肿瘤内科学会(ESMO)年会与2020年的美国临床肿瘤学会-泌尿生殖系统肿瘤研讨会(ASCO-GU)已经发布。本文将带来PROfound研究的结果以及最新的结果更新。

关键词: 转移性去势抵抗性前列腺癌, 奥拉帕利, PROfound

Abstract: Metastatic castrate-resistant prostate cancer (mCRPC) is the last stage of prostate cancer. Although new hormonal agents and taxane-based chemotherapies occurred for mCRPC treatment, the overall survival of mCRPC patients is limited. Olaparib is an inhibitor of poly ADP-ribose polymerase (PARP), which has a key role in DNA damage response. It has been approved for ovarian cancer and breast cancer treatment.  PROfound, a phase III clinical trial of olaparib in mCRPC treatment, has been reported in 2019 ESMO and 2020 ASCO-GU. In this paper, we will bring the results and updates of PROfound.

Key words: metastatic castrate-resistant prostate cancer, olaparib, PROfound

中图分类号: